title: Preoperative thromboxane A2/prostaglandin H2 receptor activity predicts early graft thrombosis.
abstract: OBJECTIVE
  This study was carried out to determine whether early failure of infrainguinal bypass grafts is associated with increased expression of platelet thromboxane A2/prostaglandin H2 (TXA2/PGH2) receptors. A prospective correlation of preoperative platelet TXA2/PGH2 receptor-mediated activity with lower extremity graft patency was sought.
  
  
  METHODS
  Twenty-five patients who underwent infrainguinal bypass surgery for limb salvage were studied at an inpatient academic tertiary referral center and Department of Veterans Affairs Medical Center. Outcome measures were primary graft patency rate at 3 months, platelet TXA2/PGH2 receptor activity by equilibrium binding with 125I-BOP, and aggregation to the TXA2-mimetic U46619.
  
  
  RESULTS
  Preoperative platelet TXA2/PGH2 receptor density was higher (Bmax, 3100 +/- 1300 vs 1500 +/- 1100 sites/platelet [mean +/- SD]; p = 0.004) in the five patients who had graft thrombosis within 3 months. The EC50 for U46619 was lower (26 +/- 6 nmol/L vs 57 +/- 30 nmol/L; p < 0.05) in these patients as well, confirming the functional effect of the increased receptor density. Early graft thrombosis was more likely in patients with a platelet TXA2/PGH2 receptor density greater than 3000 sites/platelet (odds ratio, 76; 95% confidence interval, 3.9 to 1500) or an EC50 for U46619 less than 30 nmol/L (odds ratio, 16; 95% confidence interval, 1.4 to 180).
  
  
  CONCLUSIONS
  Elevated platelet TXA2/PGH2 receptor levels and enhanced sensitivity of platelet aggregation to TXA2 predict early arterial graft thrombosis. Specific TXA2/PGH2 receptor antagonism may prevent one of the mechanisms that contributes to early graft occlusion.
authors.affiliation: Department of Surgery, Medical University of South Carolina, Charleston, USA.
authors.forename: T E
authors.initials: TE
authors.lastname: Brothers
authors.forename: J G
authors.initials: JG
authors.lastname: Robison
authors.forename: B M
authors.initials: BM
authors.lastname: Elliott
authors.forename: J M
authors.initials: JM
authors.lastname: Boggs
mesh_terms: D019796:15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid / Q000494:pharmacology; D000368:Aged; D001792:Blood Platelets / Q000378:metabolism*; D005260:Female; D006083:Graft Occlusion, Vascular / Q000453:epidemiology*; D006801:Humans; D008297:Male; D016491:Peripheral Vascular Diseases / Q000601:surgery; D010974:Platelet Aggregation / Q000187:drug effects; D011446:Prospective Studies; D011463:Prostaglandins H / Q000378:metabolism; D011982:Receptors, Prostaglandin / Q000378:metabolism*; D017482:Receptors, Thromboxane / Q000378:metabolism*; D044244:Receptors, Thromboxane A2, Prostaglandin H2; D013927:Thrombosis / Q000453:epidemiology*; D014654:Vascular Patency
chemical_list: D011463:Prostaglandins H; D011982:Receptors, Prostaglandin; D017482:Receptors, Thromboxane; D044244:Receptors, Thromboxane A2, Prostaglandin H2; D019796:15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid